Liver embolisation for patients with neuroendocrine neoplasms: systematic review induced lymphocytopenia in lung cancer
McNamara, Mairead G
Hubner, Richard A
Valle, Juan W
AffiliationManchester Medical School, The University of Manchester, Manchester,
MetadataShow full item record
AbstractBackground: Liver embolisation is one of the treatment options available for patients diagnosed with neuro-endocrine neoplasms (NEN). It is still uncertain whether the benefits of the various types of embolisation treatments truly outweigh the complications in NENs. This systematic review assesses the available data relating to liver embolisation in patients with NENs. Methods: Eligible studies (identified using MEDLINE-PubMed) were those reporting data on NEN patients who had undergone any type of liver embolisation. The primary end points were best radiological response and symptomatic response; secondary end-points included progression-free survival (PFS), overall survival (OS) and toxicity. Results: Of 598 studies screened, 101 were eligible: 16 were prospective (15.8%). The eligible studies included a total of 5,545 NEN patients, with a median of 39 patients per study (range 5-214). Pooled rate of partial response was 36.6% (38.9% achieved stable disease) and 55.2% of patients had a symptomatic response to therapy when pooled data were analysed. The median PFS and OS were 18.4 months (95% CI 15.5-21.2) and 40.7 months (95% CI 35.2-46.2) respectively. The most common toxicities were found to be abdominal pain (48.8%) and nausea (48.1%). Outcome did not significantly vary depending on the type of embolisation performed. Conclusion: Liver embolisation provides adequate symptom relief for patients with carcinoid syndrome and is also able to reach partial response in a significant proportion of patients and a reasonable PFS. Quality of studies was limited, highlighting the need of further prospective studies to confirm the most suitable form of liver embolisation in NENs.
CitationKanabar R, Barriuso J, McNamara MG, Mansoor W, Hubner RA, Valle JW, et al. Liver embolisation for patients with neuroendocrine neoplasms: systematic review. Neuroendocrinology. 2020 Mar 13
- Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
- Authors: Swierz MJ, Storman D, Riemsma RP, Wolff R, Mitus JW, Pedziwiatr M, Kleijnen J, Bala MM
- Issue date: 2020 Mar 12
- Hepatic surgery for metastases from neuroendocrine tumors.
- Authors: Sarmiento JM, Que FG
- Issue date: 2003 Jan
- Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study.
- Authors: Walter T, Lepage C, Coriat R, Barbier E, Cadiot G, Caroli-Bosc FX, Aparicio T, Bouhier-Leporrier K, Hentic-Dhome O, Gay F, Dupont-Gossart AC, Duluc M, Lepere C, Lecomte T, Smith D, Petorin C, Di-Fiore F, Ghiringhelli F, Legoux JL, Guimbaud R, Baudin E, Lombard-Bohas C, de Baère T, FFCD 1104 investigators/investigators.
- Issue date: 2019 Dec
- Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases.
- Authors: Riemsma RP, Bala MM, Wolff R, Kleijnen J
- Issue date: 2013 Apr 30
- Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
- Authors: Zhang J, Kulkarni HR, Singh A, Niepsch K, Müller D, Baum RP
- Issue date: 2019 Mar